Teva and Champions Oncology agree new collaboration

Teva has entered into a new collaboration with Champions Oncology, a developer of technology solutions and services for the development of personalised cancer therapies.

The partnership will see Teva utilise Champions' TumorGraft platform to enhance and accelerate the clinical development of several of Teva's oncology compounds, in exchange for an upfront fee and milestone-based payments.

Its aim is to identify highly responsive cancer subtypes and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapies, thus enabling the creation of better targeted treatment approaches.

The process will include screening studies on TumorGraft models to develop response hypotheses for different tumour types and sub-populations, with resulting hypotheses to be refined and validated in later studies.

Joel Ackerman, chief executive officer of Champions, said: "We are excited to announce this opportunity for us to work with the team at Teva to identify and validate sub-populations that are best suited for these compounds."

Last month, the company was granted European regulatory approval for Lonquex, its new therapy for combating neutropenia among patients receiving chemotherapy.